cd34+cells

Sarmustine (SarCNU) is an alkylating agent with anticancer activity that inhibits the growth of prostate cancer cells via p53-dependent and p53-independent pathways.Sarmustine mediates the selection of P140K methylguanine-DNA-methyltransferase-transduced human CD34(+) cells in vitro.

CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin.

OAC1 (BAS 00287861) is a compound activating Octamer-binding transcription factor 4 (Oct4). It enhances the iPSC reprogramming efficiency and accelerates the reprogramming process.

Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.

StemRegenin 1 Hydrochloride is an aryl hydrocarbon receptor (AhR) antagonist (IC₅₀ = 127 nM) that inhibits RANKL-induced osteoclast generation and differentiation while promoting the expansion of multipotent haematopoietic progenitor cells derived from human embryonic stem cells (hESCs).

Debio 0617B is a multi-kinase inhibitor that reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. debio 0617B targets key kinases upstream of STAT3/STAT5 signalling, such as JAK, ABL, SRC and class III/V receptor tyrosine kinases. debio 0617B can be used to study STAT3 driven solid tumours.

MEISi-1 is a small-molecule inhibitor targeting the homeodomain of MEIS1 protein. MEISi-1 can significantly inhibit the activity of luciferase reporter genes containing MEIS binding sites, and promote the self-renewal of key hematopoietic stem cells (HSCs) in both mice and humans in vitro and in vivo. It can be used in research on hematological diseases, cardiac regeneration, cancer and other related fields.

PHA-680626 is a potent and selective PLK inhibitor. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. PHA-680626 inhibits Plk1 (IC50 = 0.53 μM), Plk2 (IC50 = 0.07 μM) and Plk3 (IC50 = 1.61 μM).

BAY-364 (BAY-299N) functions as an inhibitor targeting the second bromine domain in TAF1, demonstrating inhibitory effects on TAF1 in Kasumi-1 cells, CD34+ cells, and K562 cells with respective IC50 values of 1.0 µM, 10.4 µM, and 10.0 µM.

EPI-X4, an endogenous peptide fragment of human serum albumin (amino acids 408-423), serves as an antagonist to the chemokine (C-X-C motif) receptor 4 (CXCR4). It effectively prevents calcium mobilization and receptor internalization triggered by chemokine (C-X-C motif) ligand 12 (CXCL12) in HEK293 cells with CXCR4 expression, at concentrations between 0.8 and 1,000 µM. Moreover, EPI-X4 hampers the CXCL12-driven migration of both Jurkat T cells and human CD34+ hematopoietic stem cells. In an acute allergic airway hypereosinophilia mouse model, EPI-X4 intrinsically decreases Cxcr4-dependent inflammatory cell infiltration in airways at a dose of 16 µmol/kg. Additionally, increased urinary EPI-X4 levels, inversely related to glomerular filtration rate (GFR), are observed in chronic kidney disease patients, indicating its potential biomarker role.

MAb604.107 is a human monoclonal antibody targeting NOTCH1. It inhibits the proliferation of primary T-ALL cells and reduces CD34/CD44 expression. MAb604.107 demonstrates antitumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. It can be utilized in research on T acute lymphoblastic leukemia (T-ALL).

ASP-1948 is a human monoclonal antibody targeting NRP1/VEGF165R/CD34. It is capable of reversing the inhibitory effects of regulatory T cells and can be applied in the study of solid tumors.

MSB-0254 is a human monoclonal antibody (mAb) that targets VEGFR2/KDR/CD309. It inhibits the invasion, migration, and vasculogenic mimicry (VM) formation of U251 and primary glioma cells. Additionally, MSB-0254 suppresses the growth of U251 and GL261 cell-transplanted tumors. It reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 is applicable to research on advanced solid tumors.

INF7TAT-P55 (P55) is a peptide that facilitates the delivery of CRISPR-engineered ribonucleoproteins. It enables efficient genomic editing in T cells and is particularly effective for CD34+ hematopoietic stem and progenitor cells (HSPC).